Clinical trial
Sirolimus for Nosebleeds in HHT: A Phase II Pilot Study
NCT05269849 is registered in ClinicalTrials.gov with Unity Health Toronto as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Sirolimus for Nosebleeds in HHT: A Phase II Pilot Study
- Lead sponsor
- Unity Health Toronto
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 16, 2022
- Completion date
- December 2, 2024
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
epistaxis, hereditary hemorrhagic telangiectasia, nosebleeds